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Abstract
Background: One of the primary causes of otitis media (OM), an inflammation of the middle ear,
is the bacterium Haemophilus influenzae (HI). OM often occurs to young children, and is mostly
treated with antibiotics. Due to concerns over bacterial resistance toward antibiotics, reliable
prophylactic treatments such as administrating anti-adhesion agents are now viewed as viable
alternatives.
Results: The present study tested the feasibilty of using phosphoinositides as anti-adhesion agents
against HI cells. Cells of non-typeable HI were radiolabeled with 111- indium-oxine, pre-incubated
with various individual phosphoinositides for 15 minutes at 37°C, and incubated with a monolayer
of human pharynx carcinoma (DT 562) cells for 20 minutes at 37°C. The result showed that at 0.1
mg/mL dipalmitoylphosphatidylinositol-3,4-diphosphate (PI-3,4-PP) had the highest anti-adhesion
activity, followed by phosphatidylinositol-3-phosphate (PI-3-P) and phosphatidylinositol-4-
phosphate (PI-4-P). The anti-adhesion activity of PI-3,4-PP was dose-dependent ranging from 0.006
to 0.1 mg/mL. In addition, results from an in vivo study demonstrated that pre-incubation of HI cells
with PI-3,4-PP at 1 mg/mL suppressed the growth of HI in nasopharynx of neonatal rats.
Conclusions: These findings suggest that PI-3-P and PI-4-P and more so PI-3,4-PP may serve as
prophylactic agents against HI adhesion and colonization.
Background
Otitis media (OM) is an inflammation of the middle ear,
often seen in children younger than six year of age. OM is
caused by infection of nasopharyngeal cells by the bacte-
rium Haemophilus influenzae (HI). Complications of OM
include permanent hearing loss and perforation of the
tympanic membrane.
Generally, OM is treated with antibiotics such as penicil-
lin derivatives. However, in spite of the effectiveness of
antibiotic prophylaxis, the increasing bacterial resistance
to antibiotics has caused some concerns. This has
prompted the development of anti-adhesive agents
against HI infection [1]. Today, several anti-adhesive
agents such as xylitol and oligosaccharides have been
studied in clinical trials [2-5]. Human casein has been
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shown to have an inhibitory effect on the adhesion of HI
to human respiratory tract epithelial cells [6], but the
active factor(s) has not been characterized. Recently, we
have discovered that certain rice flour extract inhibits HI
adhesion [7]. Results from the preliminary purification
process indicated that the active factor(s) in the rice flour
extract was amphiphilic and structurally resemble to the
phosphoinositides. To verify this view, we examined in
this study the anti-adhesion activities of phosphoi-
nositides against HI using the models of human pharynx
carcinoma (DT 562) cells and neonatal rats.
Results and Discussion
Bioactivity of polyphosphoinositides
The attachment (adhesion) of bacteria to a mammal's
nasopharynx area is believed to be the first stage of the
bacterial infection, which can lead to OM and other disor-
ders and diseases caused by HI. For this study, in vitro
effect of various phosphoinositides on the attachment of
HI to nasopharyx was evaluated. The activity was defined
as the percent of inhibition of HI adhesion to human
pharynx carcinoma cells as compared to the control.
Results in Table 1 show that four phosphoinositides, i.e.,
Ins-1,2,6-PPP, Ins-1,3,4-PPP, GPI and PI at a concentra-
tion of 0.1 mg/mL exerted no effect on HI adhesion to the
human pharynx cell cultures. On the other hand, PI-3-P
and PI-4-P showed 24% inhibition of HI adhesion. More,
PI-3,4-PP at the same concentration showed 74% inhibi-
tion against HI adhesion. A dose-dependent inhibition of
HI adhesion by PI-3,4-PP was observed between 0.006
and 0.1 mg/mL, which exerted 31 to 81% inhibition (Fig-
ure 1).
In Vivo Activity of PI-3,4-PP
The inhibitory activity of PI-3,4-PP against the attachment
of nontypeable HI was further demonstrated in two trials
using a neonatal rat model. Figure 2 shows the average
inoculum dose (cfu) and the average number (log10 [cfu/
mL]) of HI recovered for a total of 10 rat pups for each
treatment. In trial 1, at the inoculum dose of approxi-
mately 100 cfu/pup, the treated group (PI-3,4-PP) con-
taining 1 mg/mL of PI-3,4-PP showed an 80-fold (1.9
logs) reduction in the number of bacteria recovered 24
hours post-inoculation as compared to the control group
(HBSS). In trial 2, the rat pups were exposed to much
higher doses (approximately 700 cfu/pup) of bacteria.
The treated group (PI-3,4-PP), which was protected by the
same level of PI-3,4-PP, showed a 4-fold (0.6 log) reduc-
tion in the number of bacteria recovered. The result dem-
onstrates that PI-3,4-PP can inhibit the attachment and
thus the growth of nontypeable HI in the nasopharynx of
neonatal rats.
The exact mechanism for the anti-adhesion activity of the
phosphoinositides is not known at this time. However,
the anti-adhesion activity may be associated with the
structures of the phosphoinositides. Molecules containing
no phosphatidyl group such as Ins-1,2,6-P, Ins-1,3,4-P
and GPI, exerted no effects on adhesion. PI, which con-
tains a phosphatidyl group, also had no activity. In
addition to the presence of a phosphatidyl group,
phosphorylation of inositol seems to be required for the
bioactivity. Since PI-3,4-PP had a higher anti-adhesion
activity than PI-3-P and PI-4-P, it is possible that the pres-
ence of extra phosphate groups at the positions 3 and 4 of
the inositol moiety may exert an even greater effect.
Results from a preliminary study (Jeffrey Baxter, personal
communication) showed the presence of multi-phos-
phate groups in a molecule (such as phytate, inositol
phosphate, and phosvitin) were inhibitory to HI adhe-
sion. On the other hand, results from our study showed
that PI-3,4-PP was more active than phytate (a myo-inosi-
tol hexaphosphate), myo-inositol penta-and tetra-phos-
phates (data not shown). Taken together, these results
suggests that the presence of both a phosphatidyl group
and an additional phosphate group is essential for the
high anti-adhesion activity of PI-3,4-PP as compared to
PI-3-P and PI-4-P.
It is known that bacterial adhesion involves specific recog-
nition of carbohydrate receptors by pathogen proteins [4].
This specificity is probably one of the main factors that
dictate in which tissue that pathogen species can success-
fully colonize. Previously, the anti-adhesion effect of
some oligosaccahrides has been attributed to their bind-
ings to the specific binding sites of pathogen's proteins
[4]. These oligosaccharides serve as decoys and occupy
bacteria's carbohydrate-binding proteins, and thus reduce
the binding of pathogens to the native carbohydrate in
epithelial cell membrane. Similarly, polyphosphoi-
nositides present in inner ear tissue and kidney [8,9] and
other tissues have been postulated as in vivo receptor for
aminoglycoside antibiotics [10]. It is possible that phos-
phorylated phosphatidylinositol such as PI-3-P, PI-4-P,
and PI-3,4-PP may serve as decoys by occupying the bind-
Table 1: Bioactivities (% inhibition) of phosphoinositides against 
the adhesion by Haemophilus influenzae
Compound % Inhibition Dose (mg/mL)
Ins-1,2,6-PPP 6a 0.1
Ins-1,3,4-PPP -1 0.1
GPI -3 0.5
PI -2 0.1
Pl-3-P 24 0.1
Pl-4-P 24 0.1
PI-3,4-PP 74 0.1
a Within statistical error; thus no activity is presumed.Lipids in Health and Disease 2004, 3:20 http://www.lipidworld.com/content/3/1/20
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ing sites in bacteria and prevent their attachment to the
epithelial cells. It has also been reported that phosphati-
dylinositides can bind to mCD14, a cell-surface receptor
on the membrane of monocytes and neutrophils [11].
Among those tested phosphatidylinositides, PI-3-P, PI-4-
P, PI-3,4-PP, and PI-4,5-PP display the highest affinities
for mCD14. Recently, non-typeable HI have been shown
to adhere to human bronchial epithelial cells through the
lipooligosaccharide (LOS) on the cell surface of the bacte-
ria [12], and LOS further interacts with the platelet-acti-
vating factor (PAF) receptor to initiate host cell signal
cascade and bacterial invasion [13]. It is then possible that
phosphatidylinositides occupy the binding sites of the
bronchial epithelial cells through binding to the mem-
brane of these cells, thus reducing the number of binding
sites available for HI attachment. By suppressing the bind-
ing of HI to the cell membrane, phosphatidylinositides
prevents the replication of the bacteria.
Conclusions
In conclusion, the PI-3,4-PP suppressed the adhesion of
nontypeable HI to nasopharyngeal cells of neonatal rats,
and thus preventing the replication of the bacteria in the
animal. The results suggest that the phosphoinositides
may be used to formulate pharmaceutical and nutritional
compositions for prophylactic treatments of OM and
other infections caused by HI.
Materials and Methods
Phosphoinositides
Five different classes (I through V) of phosphoinositides
were used for this study (Figure 3). Class I included 1-D-
myo-inositol-1,2,6-triphosphate sodium salt (Ins-1,2,6-
PPP) and 1-D-myo-inositol-1,3,4-triphosphate sodium
salt (Ins-1,3,4-PPP) (Figure 3A). Class II included 1-(α-
glycerophosphoryl)-D-myo-inositol lithium salt (GPI),
class III L-α-phosphatidylinositol ammonium salt (PI),
class IV dipalmitoylphosphatidyl-inositol-3-phosphate
ammonium salt (PI-3-P), and L-α-phosphatidylinositol-
4-monophosphate sodium salt (PI-4-P), and class V
dipalmitoylphosphatidylinositol-3,4-diphosphate
ammonium salt (PI-3,4-PP) (Figure 3B). Ins-1,2,6-PPP,
Ins-1,3,4-PPP, PI-3-P, and PI-3,4-PP were obtained from
Matreya Inc. (Pleasant Gap, PA), GPI from Calbiochem-
Novabiochem Corp. (La Jolla, CA), and PI and PI-4-P
from Sigma Chemical Co. (St. Louis, MO). All chemicals
are reagent grade with purity greater than 99%.
Cell Cultures
The Detroit 562 human pharynx carcinoma cell line (DT
562) was obtained from the American Culture Type Col-
lection. The DT 562 cells were seeded into Costar 96-well
plates (Corning Life Science, Acton, MA) at a density of
20,000 to 25,000 cells per well, and cultured in Dulbeco's
modified Eagle Medium (GIBCO, Grand Island, NY)
supplemented with 10% fetal bovine serum (FBS)
(Hyclone, Logan, UT). The plates were incubated in a
humidified atmosphere of 95% air: 5% CO2 at 37°C until
reaching at least 90% confluency. Plates were washed
three times with 20 mL of Hanks Balanced Saline Solution
(HBSS) (Sigma Chemical Company, St. Louis, MO) to
remove serum proteins.
Radiolabeling of HI bacteria
For the adhesion study, an HI nontypeable bacterial strain
was used. The HI isolated from the middle ear of an
infected child was a gift from Dr. Lauren Bakaletz of The
Ohio State University, Columbus, Ohio. HI was streaked
onto Chocolate agar plates (Becto Dickinson Diagnostic
Instrument System, Sparks, MD) from frozen aliquots of a
The dose response curve of PI-3,4-PP against the adhesion by  H. Influenzae Figure 1
The dose response curve of PI-3,4-PP against the adhesion by 
H. Influenzae.
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In vivo activity of 1 mg/mL of PI-3,4-PP against the adhesion by 
H. influenzae.
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low passage number. The plates were then incubated at
37°C in a humidified atmosphere of 95% air: 5% CO2 for
18 hours. Bacteria were then harvested in phosphate buff-
ered solution (PBS) supplemented with 0.05% bovine
serum albumin (BSA) (Miles Inc., Kankakee, Ill.). After
centrifugation, the cell pellets were resuspended in a vol-
ume of PBS/BSA yielding an optical density of 2.4 at a
wavelength of 660 nm. The bacteria were then radiola-
belled with 111-Indium-oxine (111-  In), a high energy,
short-lived tracer. Fifty µCi of 111-In solution was added to
2.5 mL of the bacterial suspension and incubated for 20
minutes at 37°C. The radiolabeled bacteria were then
washed two times with 10 mL HBSS and unbound 111- In
were removed by centrifugation. The bacteria pellets were
then resuspended in 5 mL HBSS supplemented with 30
mM 2-hydroxyethyl-piperazine-N'-2-ethane sulfonic acid
buffer (Life Technologies, Calsbad, CA).
Adhesion Quantitation
Prior to adhesion test, aliquots (25 µL) of the 111- In-
labeled bacterial suspension were pre-incubated with 25
µL of the test chemical (containing various phosphoi-
nositides) in a Costar polypropylene 96-well plate for 15
minutes at 37°C to allow binding of the test agent to the
HI. For adhesion quantitation, aliquots (25 µL) of the pre-
incubated mixture were pipetted into the wells of an assay
plate containing the DT 562 human pharynx carcinoma
cells. The assay plate was incubated for about 15 to 20
minutes at 37°C to allow adhesion of the bacteria to the
cell monolayer. Nonadherent bacteria were removed by
washing the plate three times with HBSS. The cell monol-
ayer and the adhering of the HI cells were disrupted by the
addition of 100 µL of 0.05 N sodium hydroxide. The con-
tents of each well were placed in Cobra polypropylene
tubes and the radioactivity counted on a Cobra Gamma
Counter (Packard Instrument Co., Meriden, CT). After cal-
ibration of the background, the average radiation count of
four replicates (per sample) was calculated. The percents
of inhibition of bacterial adhesion, as compared to bacte-
rial attachment in control wells containing no test chemi-
cal were then calculated.
In Vivo Activity
A neonatal rat model [14,15] was modified for testing the
in vivo activity of PI-3,4-PP against nontypeable HI. Prior
to the test, overnight cultures of nontypeable HI were pre-
pared, washed twice and diluted with HBSS to obtain a
bacterial suspension of less than 105  colony-forming-
units (cfu) per mL. Three different test chemicals were pre-
pared for this test: (i) HI + PI-3,4-PP, an aliquot (0.5 mL)
of PI-3,4-PP (2 mg/mL in HBSS) mixed with 0.5 mL of the
diluted bacterial suspension (5 × 104 cfu/mL) and incu-
bated for one hour at 37°C; (ii) HI + HBSS, This bacterial
control prepared by mixing and incubating 0.5 mL HBSS
with 0.5 mL of the diluted bacterial suspension; and (iii)
HBSS, the solvent blank prepared by incubating 1 mL of
HBSS under the same conditions. A 10 µL of the test mate-
rial was used to inoculate 24-hour-old or younger Sprague
Dawley rats (Charles River, Portage, MI) by intranasal
administration. Twenty-four hours after the inoculation,
samples of nasopharyngeal fluid were collected by the
slow instillation of 25 µL of HBSS into the left naris, and
the initial 10-µL discharge from the right naris was col-
lected for plate count. This procedure insured that the
fluid had passed through the nasopharynx. The nasal
wash was then spread (or diluted and then spread), onto
Chocolate agar plates. The plates were incubated at 37°C
overnight and counted for the number of cfu's, an indica-
tor of the number of viable bacteria.
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Structural formulas of the five (I through V) classes of 
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